AI-generated summary
The authors randomized 40 people with chronic ischemic stroke to 980 nm transcranial near-infrared laser or a sham procedure, both alongside standard rehabilitation. They report no significant between-group difference in NIHSS change or secondary outcomes, and no adverse events. The study was described as underpowered for the small effect observed.
- Participants
- 40
- Who or what was studied
- Adults with chronic ischemic stroke (more than 6 months post-onset, NIHSS 7-22)
- Wavelengths
- 980 nm
- Limits stated in the abstract
- The abstract states the trial was underpowered (12 percent) and results apply only to the 980 nm wavelength and chronic phase, not acute stroke or other parameters.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on j-saudi-heart.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 980 nm
- Power
- 6W
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Stroke, Sham, Near-infrared, Laser, Transcranial photobiomodulation, Photobiomodulation, Neuromodulation, Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.